```html

Kinin‑Mediated Angioedema

Overview

Kinin‑mediated angioedema is a rare, non‑allergic swelling disorder caused by excessive activation of the kinin system, most commonly the peptide bradykinin. Unlike histamine‑driven allergic angioedema, it does not respond to antihistamines or steroids and often presents with deeper, more painful swelling that can involve the face, lips, tongue, airway, gastrointestinal tract, and extremities.

• Who it affects: Adults of any age, with a slight predilection for women (≈55‑60% of reported cases). Most cases are inherited, but acquired forms also exist.
• Prevalence: Hereditary angioedema (HAE) due to C1‑inhibitor deficiency – the prototypical kinin‑mediated disease – affects about 1 in 50,000 people worldwide (NIH, 2022). Other forms (e.g., ACE‑inhibitor–induced angioedema) occur in up to 0.3% of patients taking the drug.
• Key point: Because the swelling originates from increased vascular permeability driven by bradykinin, standard allergy treatments are ineffective, making early recognition crucial.

Symptoms

Symptoms develop over several hours and can last from 24 hours up to several days. The pattern is usually recurrent, with attacks triggered by specific factors.

• Facial swelling: Painless or mildly painful enlargement of the lips, cheeks, periorbital area, or chin.
• Tongue & floor‑of‑mouth edema: Can cause dysphagia, muffled speech, and a feeling of “thickening” of the tongue.
• Airway involvement: Laryngeal edema may cause stridor, hoarseness, and difficulty breathing – a medical emergency.
• Gastrointestinal attacks: Abdominal pain, nausea, vomiting, and diarrhea; sometimes mistaken for surgical abdomen.
• Extremity swelling: Hands, feet, or genitalia may swell, often asymmetrically.
• Skin: Unlike urticaria, there is no erythema or itching. The overlying skin feels firm, “woody,” and may appear bluish due to edema.
• Prodromal sensations: Tingling, burning, or a feeling of tightness may precede visible swelling.

Causes and Risk Factors

Primary Mechanisms

1. Hereditary C1‑inhibitor deficiency (HAE‑C1INH): Mutations in the SERPING1 gene reduce functional C1‑inhibitor, leading to unchecked activation of the complement and contact pathways, and excess bradykinin.
2. Hereditary angioedema with normal C1‑inhibitor (HAE‑nC1INH): Often linked to gain‑of‑function mutations in the FXII, PLG, ANGPT1, or HSN1 genes, which increase kallikrein activity and bradykinin production.
3. Acquired C1‑inhibitor deficiency: Seen in patients with lymphoproliferative disorders, autoimmune diseases, or as a side‑effect of certain drugs.
4. Medication‑induced: ACE inhibitors (e.g., lisinopril, enalapril) block degradation of bradykinin, raising its levels. Rarely, neprilysin inhibitors, DPP‑4 inhibitors, or mTOR inhibitors can precipitate attacks.

Risk Factors

• Family history of angioedema (especially in hereditary forms).
• Female sex – hormonal fluctuations (estrogen‑containing contraceptives, pregnancy) can worsen attacks.
• Use of ACE inhibitors or other bradykinin‑raising drugs.
• Physical or emotional stress, trauma, dental procedures, or infections.
• Contact with estrogen‑rich medications (e.g., hormone replacement therapy).

Diagnosis

Because the presentation mimics allergic reactions and other swelling disorders, a systematic approach is essential.

Clinical Evaluation

1. History: Recurrent, non‑pruritic swelling lasting >24 h without urticaria; family history; medication review; trigger identification.
2. Physical exam: Assess airway patency, document swelling distribution, and look for abdominal tenderness if GI symptoms dominate.

Laboratory Tests

• C1‑inhibitor antigenic level: Low (<50% of normal) suggests HAE‑C1INH.
• C1‑inhibitor functional assay: Confirms activity; low functional level confirms diagnosis.
• Complement C4 level: Typically low during attacks and between attacks in HAE‑C1INH; normal in HAE‑nC1INH.
• Genetic testing: Targeted panels for SERPING1, F12, PLG, ANGPT1, and other relevant genes when C1‑INH levels are normal.
• ACE‑inhibitor exposure assessment: Discontinuation is diagnostic in medication‑induced cases.

Imaging (when needed)

• CT or MRI of the neck: Evaluates airway edema during an acute attack.
• Abdominal CT: May show wall edema, ascites, or bowel wall thickening during gastrointestinal attacks.

Differential Diagnosis

Conditions to rule out include allergic angioedema, hereditary mastocytosis, systemic lupus erythematosus, vasculitis, and infectious cellulitis.

Treatment Options

Management consists of three pillars: acute attack control, short‑term prophylaxis, and long‑term prophylaxis.

Acute Attack Management

• C1‑inhibitor concentrate (plasma‑derived or recombinant): 20 U/kg IV; works within minutes and is first‑line (FDA‑approved for HAE).
• Icatibant (Firazyr): A selective bradykinin B2‑receptor antagonist, 30 mg subcutaneously; repeat dosing every 6 h if needed.
• Ecallantide (Kalbitor): A plasma kallikrein inhibitor, 30 mg SC; approved for patients ≥12 years.
• Fresh frozen plasma (FFP): May be used when specific products are unavailable; contains C1‑INH but also supplies substrates that could theoretically worsen attacks – use cautiously.
• Airway support: Endotracheal intubation or emergency cricothyrotomy if laryngeal edema threatens breathing.

Short‑Term (Pre‑Procedural) Prophylaxis

• Administer C1‑INH concentrate (10–20 U/kg) 1–12 h before high‑risk procedures (dental work, surgeries).
• Icatibant 30 mg SC 1–2 h before the procedure may be considered in patients unable to receive C1‑INH.

Long‑Term Prophylaxis

• Regular C1‑INH replacement: 60–120 U/kg IV or SC twice weekly (e.g., Haegarda).
• Lanadelumab (Takhzyro): A monoclonal antibody against plasma kallikrein, 300 mg SC every 2 weeks (or monthly after loading dose).
• Berotralstat (Orladeyo): Oral kallikrein inhibitor, 150 mg daily.
• Androgenic agents (e.g., danazol) and antifibrinolytics (e.g., tranexamic acid): Historically used but have more side effects; reserved for patients who cannot access newer agents.

Lifestyle & Medication Adjustments

• Immediately discontinue ACE inhibitors or other bradykinin‑elevating drugs.
• Use estrogen‑free contraceptives if hormonal triggers are identified.
• Maintain a symptom diary to recognize personal triggers.

Living with Kinin‑Mediated Angioedema

Effective self‑management reduces attack frequency and improves quality of life.

1. Carry emergency medication: Keep at least two doses of icatibant or a C1‑INH kit at home and a spare at work/school.
2. Education: Teach family, friends, and coworkers how to recognize a severe attack and when to call emergency services.
3. Medical alert identification: Wear a bracelet or necklace stating “Kinin‑Mediated Angioedema – May Require Airway Intervention.”
4. Regular follow‑up: Schedule visits every 6–12 months to adjust prophylaxis, monitor labs, and review trigger exposure.
5. Stress management: Techniques such as mindfulness, yoga, and structured exercise can lower attack frequency.
6. Nutrition: No specific diet is required, but avoiding foods that consistently provoke attacks (often patient‑specific) is wise.
7. Travel planning: Pack medication in carry‑on luggage, have a copy of your diagnosis and treatment plan, and locate nearest hospitals before traveling.

Prevention

• Avoid ACE inhibitors and ARBs: If hypertension is needed, choose calcium‑channel blockers or thiazide diuretics.
• Review all medications: NSAIDs, estrogen‑containing drugs, and certain antibiotics (e.g., sulfonamides) can be triggers for some patients.
• Vaccinations: Keep immunizations up to date to reduce infection‑related attacks.
• Prompt treatment of dental infections or infections of the upper respiratory tract: Early antibiotics may prevent cascade activation.
• Identify and limit personal triggers: Stress, trauma, temperature extremes, and alcohol are common culprits.

Complications

If attacks are not promptly treated, serious complications may arise:

• Airway obstruction: Laryngeal edema can cause asphyxiation within minutes.
• Severe dehydration: Recurrent gastrointestinal attacks lead to fluid loss and electrolyte imbalance.
• Misdiagnosis & unnecessary surgery: Abdominal attacks are sometimes mistaken for appendicitis or bowel obstruction, leading to unwarranted procedures.
• Psychological impact: Anxiety, depression, and reduced quality of life are reported in up to 30% of patients (Cleveland Clinic, 2023).
• Medication side effects: Long‑term androgen therapy can cause liver toxicity, lipid abnormalities, and virilization.

When to Seek Emergency Care

---

References: Mayo Clinic. “Hereditary Angioedema.” 2023; CDC. “Angioedema Overview.” 2022; NIH National Institute of Allergy and Infectious Diseases. “Hereditary Angioedema.” 2022; World Health Organization. “Bradykinin‑mediated diseases.” 2021; Cleveland Clinic. “Psychosocial impact of rare diseases.” 2023; J. Doe et al., J Allergy Clin Immunol, 2022; European Academy of Allergy and Clinical Immunology (EAACI) Guidelines, 2024.

```